The ADD2 antibody targets ADD2 (Adducin 2), also known as β-adducin, a member of the adducin family of cytoskeletal proteins. Adducins are critical for stabilizing and organizing the spectrin-actin network in cell membranes, particularly in erythrocytes and neurons. ADD2. encoded by the ADD2 gene, is predominantly expressed in the brain, kidney, and hematopoietic tissues. Structurally, it consists of an N-terminal globular head, a neck domain, and a C-terminal tail that facilitates interactions with spectrin and actin. Phosphorylation at specific residues modulates its activity, influencing membrane mechanical stability, cell-cell adhesion, and ion transport.
Dysregulation of ADD2 has been implicated in various pathological conditions. Genetic variants are associated with hypertension due to altered renal sodium handling, while reduced expression in erythrocytes may contribute to hemolytic disorders. In neurons, ADD2 dysfunction is linked to synaptic plasticity impairments and neurodegenerative diseases. Additionally, aberrant ADD2 expression has been observed in certain cancers, suggesting a role in tumor progression.
ADD2 antibodies are essential tools in biomedical research, enabling detection and localization of the protein via techniques like Western blotting, immunohistochemistry, and immunofluorescence. These antibodies aid in studying ADD2’s physiological roles, post-translational modifications, and involvement in disease mechanisms, offering insights for therapeutic targeting. Their specificity and reliability are validated across diverse experimental models, from cellular assays to animal studies.